Company ProfilePremium

Actinogen Medical Limited

Company Profile Analysis

Ticker: ACW.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Actinogen Medical Limited - Company showcase

Year Founded & Workforce

1999

6 Employees

Actinogen Medical Limited logo

Actinogen Medical Limited Employee Contacts

4 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Actinogen Medical Limited Overview

Actinogen Medical is a Sydney-based, ASX-listed, clinical-stage biotechnology company with a single platform asset, Xanamem (emestedastat), a brain-penetrant, once-daily oral inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which regenerates active cortisol inside brain cells. The company's thesis is that chronically elevated brain cortisol damages neurons and contributes to cognitive decline and mood disorders, and that lowering it intracellularly can slow Alzheimer's disease (AD) progression and treat depressive symptoms. Its pivotal Phase 2b/3 XanaMIA trial (247 participants with biomarker-confirmed progressive mild-to-moderate AD, 10 mg vs placebo over 36 weeks) completed its last patient visit on 22 September 2026, with topline results guided for November 2026. Actinogen positions Xanamem as a convenient oral alternative or complement to infusion-based anti-amyloid antibodies, avoiding the MRI-monitoring burden associated with ARIA. Pre-revenue, it funds itself through equity raisings and Australia's refundable R&D Tax Incentive.


What the company does

Actinogen is a drug developer, not a commercial-stage pharmaceutical company. Its entire enterprise value rests on Xanamem. The company in-licensed/acquired the molecule (originally discovered at the University of Edinburgh, coded UE2343) through its acquisition of Corticrine Limited in the mid-2010s, then reshaped itself from an earlier natural-products (actinomycete-derived antibiotic) discovery business into a neuroscience company.

The company's own description (repeated in ASX announcements and the FY2025/FY2026 annual report boilerplate) is that it is developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol, targeting the substantial unmet need in cognitive dysfunction and behavioural abnormalities. In 2026 communications it describes itself as being in the late clinical stages of developing Xanamem for Alzheimer's disease and depression.

Business model

Development model: Virtual/outsourced. Clinical trials are run through contract research organisations (CROs) and investigator sites in Australia and the United States; drug substance and tablet manufacture are outsourced (commercial-grade 10 mg tablets produced at Catalent's US facility; a 15 kg drug-substance batch has been manufactured).

Monetisation pathway (stated): If XanaMIA is positive, management intends to pursue regulatory engagement on accelerated pathways (including with the US FDA), run a second, larger multinational pivotal trial (planned for 2027), and, per sponsored research commentary, seek a potentially transformative licensing/partnering deal. A Chief Commercial Officer was appointed in FY2025 and market research is under way.

Revenue model mix: Product 0%, service 0%, subscription 0%, licensing 0%. Reported "revenue and other income" is overwhelmingly the refundable Australian R&D Tax Incentive (e.g. A$12.67m of A$13.17m total income in FY2026), plus interest.

Value-chain position

Actinogen sits at the discovery/clinical-development end of the pharmaceutical value chain, owning IP and clinical data. It has no sales force, distribution or manufacturing plants. Value capture would come via (a) out-licensing to a large pharma with commercial infrastructure in neurology, (b) a co-development deal, or (c) acquisition.

Customer types and end-markets (prospective)

Ultimate patients: People aged 50+ with mild-to-moderate AD and biomarker-confirmed progressive disease (elevated plasma pTau181); patients with major depressive disorder (MDD) with cognitive impairment; historically fragile X syndrome was explored.

Prescribers: Neurologists, geriatricians, psychiatrists, and potentially primary care (an oral pill without MRI monitoring is a key differentiator versus infusion antibodies).

Payers: US Medicare/commercial payers, European national health systems, Australian PBS.

Near-term "customers": Potential pharma licensees.

Independent characterisation

Actinogen is a high-risk, binary, single-asset micro/small-cap biotech whose risk profile has been partially reduced by (i) three positive independent Data Monitoring Committee (DMC) reviews, including a January 2026 interim efficacy non-futility review, (ii) over-enrolment of XanaMIA (247 vs original target), (iii) regulatory alignment with FDA (September 2025 Type C meeting) and EMA (scientific advice, May 2026), and (iv) a funded runway beyond the readout into mid-2027. However, the mechanism has historical failures: the company's own XanADu Phase 2 trial (2019) missed its primary endpoints, and an earlier 11β-HSD1 inhibitor from a large pharma did not show efficacy in AD. The current trial's enrichment strategy (pTau181-elevated patients) is based on post-hoc analysis of XanADu, which is a recognised source of risk.

Strategy

Stated strategy (themes from FY2025–FY2026 reporting)

  1. Deliver XanaMIA — complete the pivotal Phase 2b/3 trial and report topline efficacy and safety in November 2026.

  2. Regulatory acceleration — use FDA (Sept 2025) and EMA (May 2026) alignment on a streamlined pathway; explore accelerated-approval options if results are positive.

  3. Second pivotal trial (2027) — larger, multinational, two-arm 10 mg vs placebo design.

  4. Commercial readiness — CCO appointment, market research, commercial-grade manufacturing at Catalent, 15 kg API scale.

  5. Long-term data via OLE — up to 24 months of active treatment data compared with historical controls.

  6. Depression optionality — leverage XanaCIDD's published antidepressant signal; further MDD trials contingent on independent funding/partnering.

  7. Capital discipline — combine equity, R&D tax incentive and rebate-backed lending to reach the readout without distress.

  8. Partnering — sponsored research indicates management aims for a licensing deal post-readout.

Initiatives in the last 24 months

DateInitiative
Sep 2024A$11.1m placement and SPP to fund XanaMIA expansion
2024–2025A$13.8m non-dilutive R&D tax incentive funding facility
2,025INN emestedastat obtained; FDA Type C (MDD)
2,025Chief Commercial Officer appointed; commercial market research
Sep 2025FDA Type C (AD) — pathway agreed
Feb 2026~A$16.8m capital raising
Mar 2026XanaMIA-OLE launched
May 2026EMA scientific advice received
2,026Endpoints Capital loan (A$4.32m) against FY2026 rebate
2,026Forrest Capital underwriting of unlisted options (~A$4.77m)

ESG commitments and cost-programme targets: not publicly disclosed.

Medium-term targets / guidance

No financial targets (company is pre-revenue). Operational guidance: XanaMIA topline November 2026; second pivotal trial 2027; cash runway beyond mid-2027.

Products & Services

Actinogen has no marketed products. The portfolio is a single molecule pursued across several indications.

Xanamem® (emestedastat) — core asset

AttributeDetail
ModalitySmall molecule, oral, once daily
MechanismSelective inhibitor of 11β-HSD1, the enzyme that converts inactive cortisone into active cortisol within cells; designed to cross the blood-brain barrier and lower intracellular brain cortisol
Dose in pivotal programme10 mg once daily
FormulationCommercial-grade 10 mg tablets manufactured at Catalent (USA)
OriginUniversity of Edinburgh discovery (code UE2343), acquired via Corticrine
INNEmestedastat (WHO, 2025)
TrademarkXanamem®
Differentiation claimsOral; no requirement for serial MRI safety monitoring (unlike anti-amyloid antibodies); mechanism independent of amyloid; potential for combination use
PricingNot disclosed (no approved product)

Indication programmes

Programme / trialIndicationPhaseDesignStatus (Oct 2026)
XanaMIAMild-to-moderate AD with progressive disease confirmed by elevated plasma pTau181Phase 2b/3 (pivotal)Randomised, double-blind, placebo-controlled; 10 mg vs placebo for 36 weeks; 247 participants; Australia and US sitesLast patient visit 22 Sep 2026; topline November 2026; three positive DMC reviews
XanaMIA-OLESame population (current and former XanaMIA participants)Open-label extensionActive 10 mg for up to 24 months; rolling data comparison vs historical controls and randomised phaseBegan March 2026; ~89% of eligible participants transitioned; 108 on treatment (Aug 2026)
Second pivotal AD trialADPhase 3 (planned)Two-arm, 10 mg vs placebo, larger and multinational, agreed with FDAPlanned for 2027
XanaCIDDMDD with cognitive impairment (adjunctive)Phase 2a (completed)Randomised placebo-controlledAntidepressant activity on MADRS and patient-reported scales; published in British Journal of Psychiatry (2026); further MDD trials pending independent funding/partnering
XanADuMild ADPhase 2 (completed 2019)20 mg/day, 12 weeksPrimary endpoints missed; post-hoc pTau181 subgroup signal underpins XanaMIA
XanaHESHealthy elderlyPhase 1b (completed)Cognitive effects at 10/20 mgSignals on attention/working memory
XanaFX (historical)Fragile X syndromePlanned Phase 2 (historical)—Not an active priority in 2025–2026 disclosures

Financial Narrative

Context: As a pre-revenue biotech, conventional margin, EBITDA-multiple and return metrics are mathematically negative or not meaningful. The relevant analytics are cash burn, runway, R&D intensity and funding mix.

Income statement

Notes and sources: FY2022 loss before tax of A$9,497,370 and FY2022 R&D rebate of A$3,640,082 from the FY2022 Appendix 4E (ASX, 25 Aug 2022). FY2025 net loss of A$14,732,263 and FY2024 net loss of A$13,044,282 from the FY2025 Annual Report. FY2026 net loss of A$15,379,848, total income A$13.17m, R&D rebate A$12.67m and R&D expense A$19.03m from the FY2026 results release (27 Aug 2026). FY2023 figures and FY2023–FY2025 income/SG&A splits from Stock Analysis aggregation of filings (not reconciled line-by-line). FY2026 SG&A not separately captured in sources reviewed; the residual of all non-R&D expenses (G&A, share-based payments, finance costs including the Endpoints Capital loan) is derived at approximately A$9.5m.

Margins and growth: Gross, operating, EBITDA and net margins are not meaningful (no sales). Revenue CAGR is not meaningful. The net loss CAGR FY2022–FY2026 is approximately 12.8% per year, reflecting a step-up in clinical activity rather than cost indiscipline.

Balance sheet: notes and sources

Sources: FY2025 cash A$16,504,230 (FY2025 Annual Report); FY2026 cash A$16,734,937 and FY2026 rebate accrual A$10,817,407 (FY2026 results release); Endpoints Capital loan A$4.32m (FY2026 results coverage). Interim reference points: cash A$11.47m at 31 Dec 2023 (Google Finance), A$10.41m at 30 Sep 2025 (Sep-2025 Appendix 4C), A$6.5m at 31 Dec 2025 with A$29.7m pro forma after the February 2026 raise and R&D rebate (H1 FY2026 results). Net debt: net cash position in all years (FY2026 net cash approx. A$12.4m before the rebate receivable).

Cash flow: notes and sources

Sources: Stock Analysis aggregation (FCF ≈ operating cash flow given negligible capex). FY2026 operating cash flow not captured; Q1 FY2026 operating outflow was A$6.1m (Sep-2025 4C). Year-to-year FCF volatility is largely timing of R&D rebate receipts (e.g. the FY2024 rebate of A$9.0m was received in October 2024, i.e. in FY2025, flattering FY2025 FCF).

Commentary

The five-year pattern is a steadily rising loss (A$9.5m to A$15.4m) driven by R&D (A$8.2m to A$19.0m) as XanaMIA expanded into a pivotal trial and XanaCIDD ran in parallel. The Australian R&D Tax Incentive is a material, structural offset: the FY2026 rebate of A$12.67m covered roughly two-thirds of R&D expense, which is why the net loss rose only modestly despite a 55% jump in R&D. The inflection points are FY2024 (XanaMIA scale-up, R&D +75%) and FY2026 (full enrolment, OLE start, manufacturing). Funding has come from repeated small-to-mid-size equity raisings (rights issues 2020, 2023, 2024; placement + SPP Sep 2024; ~A$16.8m Feb 2026), non-dilutive rebate-backed facilities (A$13.8m facility; Endpoints Capital loan) and option exercises (an underwriting by Forrest Capital of remaining unlisted options worth ~A$4.77m was announced). Share count growth has been substantial (~2.3bn shares at Dec 2023 to ~3.7bn implied in 2026), a dilution cost that should be weighed against the progress achieved.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsProducts

Single segment: Pharmaceutical R&D

Clinical development of Xanamem (emestedastat) across AD and MDD; manufacturing scale-up; regulatory and commercial readiness

Xanamem 10 mg oral tablet (investigational)

Results by Segment and Revenue by Segment (%)

MetricFY2024FY2025FY2026

Segment total income (AUD Mn)

9.935.4913.17

Segment net loss after tax (AUD Mn)

-13.04-14.73-15.38

Share of group income (%)

100100100

Income Statement

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from contracts with customers (AUD Mn)

00000

Total revenue and other income (AUD Mn)

3.644.899.935.4913.17

of which R&D tax rebate (AUD Mn)

3.64———12.67

R&D expense (AUD Mn)

8.218.9015.5412.3019.03

SG&A expense (AUD Mn)

3.275.055.936.46—

Net loss after tax (AUD Mn)

-9.50-10.75-13.04-14.73-15.38

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Cash and cash equivalents (AUD Mn)

———16.5016.73

R&D tax rebate receivable/accrued (AUD Mn)

————10.82

Borrowings – R&D tax-backed loan (AUD Mn)

000—4.32

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Free cash flow (AUD Mn)

-9.52-8.73-16.96-7.59—

Capex (AUD Mn)

00000

Dividends paid (AUD Mn)

00000

Buybacks (AUD Mn)

00000

Financial Analysis

RatioAssessment

ROE / ROA / ROIC

Deeply negative; not meaningful for a pre-revenue developer (Google Finance cited ROA of roughly -103% at Dec 2023)

Debt/equity

Low; only R&D-tax-backed lending

Net debt/EBITDA, interest coverage

Not meaningful (negative EBITDA, net cash)

Runway

Company guides funding beyond XanaMIA results to mid-2027 (FY2026 results; CFO commentary July 2026)

Results by Region

MetricFY2024FY2025FY2026

Australia income (AUD Mn)

9.935.4913.17

Americas income (AUD Mn)

000

EMEA income (AUD Mn)

000

Market Valuation and Share Price

MetricFY2025FY2026

Market cap at 30 June (AUD Mn)

73.07115.23

Share price at 30 June (AUD)

0.020.03

Value by Reference Point

Reference pointValue

Share price late Jan 2026

~A$0.050 (Investing.com)

Share price 26 Feb 2026 (H1 release)

A$0.041–0.046

Share price late Jul / early Aug 2026

A$0.042–0.043

Recent observation (Sep/Oct 2026, aggregators)

~A$0.037; market cap ~A$128–133m

52-week range

A$0.023 – A$0.072

1-year relative performance

Outperformed the ASX All Ordinaries by ~54% (Stockopedia, mid-2026)

Analyst Conclusions

Management guidance

  • XanaMIA topline 36-week efficacy and safety results: November 2026.

  • Ongoing rolling XanaMIA-OLE data.

  • Second, larger multinational pivotal AD trial planned for 2027.

  • Exploration of accelerated approval with FDA if results are positive.

  • Cash runway beyond mid-2027 (before any new raise).

  • No revenue or earnings guidance.

Consensus

Formal consensus revenue/EPS expectations are not meaningful; coverage is thin (~2 analysts per aggregators), with a cited target price of A$0.08.

Bull case

  1. De-risked readout: The January 2026 interim analysis cleared an efficacy non-futility bar and all three DMC safety reviews were clean, raising the probability of a positive topline above historical AD base rates.

  2. Commercial differentiation: An oral, once-daily pill without MRI monitoring would address the main practical barriers limiting uptake of anti-amyloid antibodies, in a market referenced at ~US$20bn.

  3. Funded optionality: A$16.7m cash plus A$10.8m rebate receivable fund the company beyond readout, strengthening its negotiating position for a licensing deal and preserving an MDD option backed by peer-reviewed data.

Bear case

  1. Mechanism history: XanADu failed its primary endpoints in 2019; XanaMIA's enrichment rests on a post-hoc subgroup, and oral AD agents from much larger sponsors have repeatedly failed in Phase 3.

  2. Capital intensity ahead: Even a positive result requires a larger multinational pivotal trial in 2027; without a partner, this implies heavy dilution of a share base already ~3.7bn.

  3. Single-asset fragility: With no other pipeline asset, a negative or ambiguous result would leave little residual value beyond cash.

Catalysts and monitorables (next 12 months)

TimingCatalyst
Oct 2026Annual Report lodgement (~14 Oct); September-quarter 4C
Nov 2026XanaMIA topline results (primary and key secondary endpoints, pTau-defined effect size, safety)
Nov 2026AGM
Q2 FY2027Receipt of ~A$10.8m FY2026 R&D rebate; repayment of Endpoints loan
Late 2026–2027FDA/EMA meetings on accelerated pathways; partnering discussions
2,027Second pivotal trial initiation and its funding structure
OngoingXanaMIA-OLE long-term data; scientific presentations (e.g. CTAD conference)

Analyst verdict

Actinogen Medical is approaching the defining moment of its 27-year corporate life. After pivoting from antibiotic discovery to neuroscience a decade ago and absorbing a painful Phase 2 failure in 2019, the company has rebuilt its Xanamem thesis around biomarker-selected patients, regulatory alignment and disciplined, rebate-supported funding. The operational record of the past two years is genuinely strong for a company of its size: XanaMIA over-enrolled to 247 participants, passed an interim efficacy futility test and three safety reviews, began a well-subscribed open-label extension, secured FDA and EMA input, and completed commercial-grade manufacturing — all with an annual net loss held to about A$15m thanks to Australia's R&D Tax Incentive.

Yet the investment case remains fundamentally binary. Interim non-futility is a low bar compared with demonstrating a statistically and clinically meaningful benefit over 36 weeks, and the scientific premise depends on a subgroup finding from a failed trial. The broader field has punished oral, non-amyloid hypotheses repeatedly, including from far better-resourced sponsors. At a market capitalisation of roughly A$130–160m, the market appears to be pricing a meaningful but far from certain probability of success, a reasonable stance given the asymmetric outcomes: a clearly positive readout would likely unlock partnering interest and a material rerating, while a miss would likely compress value towards cash.

For institutional readers, the prudent framing is event-driven: position sizing should reflect a high-variance outcome in November 2026, with key monitorables being the magnitude and consistency of effect across cognitive and functional endpoints, the safety profile, and management's financing or partnering plan for the 2027 pivotal trial. Governance, insider alignment (CEO ~5.5%) and disclosure quality are adequate for a micro-cap biotech; the principal unresolved issue is dilution. Overall verdict: speculative, catalyst-driven, high-risk/high-reward; neutral until the topline data are known.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / background

Dr Steven Gourlay

CEO and Managing Director

CEO since 14 March 2021; physician with prior biotech/medtech board roles (e.g. Elastagen, Applied Physiology, Endoluminal Sciences); holds ~203m shares (~5.5%) per June 2026 notices

Dr Dana Hilt

Chief Medical Officer

Leads clinical programme; US neurology drug-development veteran (details per company website)

Will Souter

Chief Financial Officer

—

Tamara Miller

SVP Product Development

Per aggregator listing

Fujun Li

Head of Manufacturing

Per aggregator listing

Peter Webse

Company Secretary

Per aggregator listing

Michael Roberts

Investor Relations

Named IR contact on ASX releases

Board of Directors

NameRoleNotes

Dr Geoffrey Brooke

Non-Executive Chair

Healthcare venture capitalist (founder of GBS Venture Partners; MedVest); also chairs Cynata Therapeutics, director of Acrux and Saluda Medical; ~39.2m shares (~1.05%)

Dr Steven Gourlay

Managing Director

Executive

Malcolm McComas

Non-Executive Director

9.8m direct shares (June 2026)

Dr George Morstyn

Non-Executive Director

Former senior R&D executive (Amgen/CSL background); ~15.2m direct shares

Dr Nicki Vasquez

Non-Executive Director

~10.9m direct shares

Competitive Landscape

Key Competitors

CompetitorAsset / approachStatus (as generally reported)Relevance to Actinogen

Eisai / Biogen

Leqembi (lecanemab), anti-amyloid IV/subcutaneous antibody

Approved (US, EU, others)

Standard of care benchmark; MRI-monitoring burden is Xanamem's key contrast point

Eli Lilly

Kisunla (donanemab), anti-amyloid antibody

Approved

Same as above

Novo Nordisk

Oral semaglutide in early AD (evoke/evoke+)

Phase 3 reported as not meeting primary endpoints (late 2025)

Showed the difficulty of non-amyloid oral approaches

Anavex Life Sciences

Blarcamesine (oral sigma-1 agonist)

EU regulatory setbacks reported

Oral competitor; cautionary precedent

Alzheon

Valiltramiprosate (oral, APOE4/4)

Phase 3 missed primary endpoint (reported 2025)

Oral competitor

Cassava Sciences

Simufilam

Discontinued after Phase 3 failures

Cautionary precedent

Athira Pharma

Fosgonimeton

Phase 2/3 failure

Cautionary precedent

Annovis Bio

Buntanetap (oral)

Phase 3 ongoing

Oral competitor

Cognition Therapeutics

Zervimesine (CT1812, oral)

Phase 2

Oral competitor

AC Immune, Prothena, others

Anti-tau/anti-amyloid antibodies and vaccines

Clinical

Disease-modifying pipeline

Sparrow Pharmaceuticals

Clofutriben (11β-HSD1 inhibitor)

Clinical in endocrine/inflammatory indications

Mechanistic peer, not in AD

Generic antidepressants / J&J (Spravato) / others

MDD therapies

Approved

Competitive context for depression programme

Peer Comparison FY2026

DimensionActinogenAnti-amyloid antibodies (Eisai/Lilly)Other oral small molecules

Route

Oral once daily

IV/SC infusion or injection

Oral

Monitoring

No MRI requirement expected (company claim)

Serial MRI for ARIA

Varies

Mechanism

Brain cortisol (11β-HSD1)

Amyloid clearance

Diverse

Stage

Pivotal Phase 2b/3 readout Nov 2026

Approved

Mostly Phase 2–3, many failures

Combination potential

Yes (mechanism-independent)

—

Varies

Company Snapshot

6

Employees

1999

Founded

Sydney, Australia

Headquarters

SWOT Analysis

Strengths

  • Pivotal XanaMIA trial fully enrolled at 247 participants, exceeding target (Dec 2025), improving statistical power.
  • Three positive independent DMC reviews, including a January 2026 interim efficacy non-futility recommendation.
  • Regulatory alignment: FDA Type C (Sept 2025) agreed a two-pivotal-trial pathway; positive EMA scientific advice (May 2026).
  • Funded through readout: FY2026 cash A$16.73m plus A$10.82m rebate accrual; runway guided to mid-2027.
  • Oral once-daily 10 mg tablet with commercial-grade supply already manufactured at Catalent.
  • Peer-reviewed depression data (British Journal of Psychiatry, 2026) giving a second indication option.
  • High OLE participation (~89% transition; 108 on treatment as of Aug 2026), suggesting tolerability and patient/caregiver acceptance.

Weaknesses

  • Single-asset concentration: all value rests on Xanamem.
  • XanADu (2019) missed its primary endpoints; the XanaMIA design relies on a post-hoc pTau181 subgroup.
  • Persistent losses (A$15.38m in FY2026) and no revenue.
  • Significant dilution: shares outstanding rose from ~2.3bn (Dec 2023) to ~3.7bn implied (2026).
  • Very small team (~6 employees per aggregators) relative to late-stage and commercial ambitions.
  • Reliance on sponsored rather than independent research coverage; thin analyst following (aggregators cite ~2 analysts).

Opportunities

  • Positive November 2026 topline could trigger a licensing deal (flagged by Edison research).
  • Possible accelerated-approval discussions with FDA if results are strong.
  • Combination use alongside anti-amyloid antibodies.
  • MDD indication (large market) via partner funding.
  • Blood-based pTau diagnostics expanding the addressable diagnosed population.
  • Long-term OLE data (up to 24 months) to strengthen the disease-modification case.

Threats

  • Binary readout: a negative result would likely impair the equity severely (precedent: ~67% fall after XanADu in 2019).
  • High failure rate of oral AD candidates (Novo, Alzheon, Cassava, Athira examples).
  • Second pivotal trial (2027) will require large capital — dilution or partnering on unfavourable terms.
  • Competitive advances in anti-tau, subcutaneous amyloid antibodies or other oral agents.
  • Changes to Australia's R&D Tax Incentive would hit the funding model (rebate = ~two-thirds of FY2026 R&D).
  • Regulatory expectations for functional (not only cognitive) endpoints.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr–Jun 2025XanaMIA recruitment accelerates in Australia and US; US patient-recruitment campaign via ClinialsDe-risks enrolment timeline
Mid-2025XanaMIA passes 100th participantProgress milestone
2025WHO assigns INN emestedastatRegulatory/identity milestone
2025FDA Type C meeting on MDDDefines depression pathway
2025Chief Commercial Officer appointedCommercial preparation
202515 kg drug-substance batch manufacturedSupply readiness
25 Aug 2025FY2025 results: net loss A$14.73m; cash A$16.50mFunding to mid/late CY2026 at the time
Sep 2025FDA Type C (AD) meeting: agreed pathway — XanaMIA + one further pivotal trialMajor regulatory clarity
15 Oct 2025FY2025 Annual Report released—
23 Oct 2025Sep-2025 quarterly 4C: operating outflow A$6.1m; cash A$10.41m; ~1.7 quarters fundingHighlighted funding need
Nov 2025AGMRoutine governance
Dec 2025XanaMIA final (247th) participant enrolledAbove target; improves power
30 Jan 2026Positive DMC interim analysis (efficacy non-futility + safety)Key de-risking event
Feb 2026~A$16.8m capital raise completedRunway to mid-2027
26 Feb 2026H1 FY2026 results: net loss A$11.3m; pro forma cash A$29.7m; commercial-grade tablets completed at CatalentFinancial position
Mar 2026XanaMIA-OLE commencesLong-term safety/efficacy data
1 Apr 2026Business update; first OLE participant treated; topline reaffirmed for November 2026Timeline confirmation
Apr 2026March-2026 quarterly 4C (and subsequent correction)Reporting
May 2026Positive EMA scientific advice on AD programmeEU pathway clarity
May 2026Edison update: 88% early OLE uptakeEngagement signal
Jun 2026Third positive DMC review (all 247 participants' safety)Safety de-risking
24 Jun 2026Director/employee share-plan issuesGovernance/dilution
2026XanaCIDD depression results published in British Journal of PsychiatryScientific validation
Jul 2026AAIC 2026 (London) poster on XanaMIA screening/enrolmentVisibility
29 Jul 2026June-2026 quarterly: cash A$16.7m; runway into mid-2027Funding
2026Response to ASX price query (share price move)Market-sensitivity marker
2026Forrest Capital underwrites remaining unlisted options (~A$4.77m)Additional funding
27 Aug 2026FY2026 results and Annual Report: net loss A$15.38m; R&D A$19.03m; rebate accrued A$10.82mAnnual reporting
22–23 Sep 2026XanaMIA last patient final visit completed; topline confirmed November 2026Final operational milestone before readout
14 Oct 2026 (scheduled)Annual report lodgement date per Market Index calendar—

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment (%): Share of group income held from 100% in FY2024 to 100% in FY2026.
Actinogen Medical Limited — Revenue by Segment (%)
Series (%)FY2024FY2025FY2026
Share of group income100100100

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Actinogen Medical, FY2026 results release and Annual Report announcement, ASX, 27 August 2026 (investorpa.com mirror of ASX PDF)
  2. Actinogen Medical, FY2025 results release, ASX, 25 August 2025 (announcements.asx.com.au)
  3. Actinogen Medical, Appendix 4E and 2022 Annual Report, ASX, 25 August 2022
  4. Actinogen Medical, positive DMC interim analysis announcement, ASX, 30 January 2026
  5. Actinogen Medical, AGM results announcements (17 Nov 2023; 14 Nov 2024)
  6. Actinogen Medical, "Actinogen commences open-label phase of XanaMIA…", GlobeNewswire, 1 April 2026
  7. Actinogen Medical, X/Twitter posts (Aug–Sep 2026) on FY2026 results and last patient visit
  8. Quartr, Actinogen H2 2026 earnings summary (27 Aug 2026)
  9. FilingReader, FY2025 Annual Report and FY2026 results summaries
  10. InvestSMART, summaries of Sep-2025 Appendix 4C and H1 FY2026 results
  11. Proactive Investors, June-quarter interview (29 Jul 2026) and market-opportunity article (4 Aug 2026)
  12. Edison Group (company-sponsored): notes of Sept 2024, 20 Feb 2026 and 19 May 2026
  13. Clinical Trials Arena (2 Apr 2026): Stocks Down Under (2 Apr 2026) · StockWire X (Feb and Sep 2026)
  14. Market Index (ACW directors, holdings, financials): Stock Analysis (income statement and FCF history) · Investing.com · Simply Wall St · Alpha Spread · Stockopedia · Google Finance · MarketScreener (director profiles) · Moomoo (management listing) · Motley Fool Australia (historical share-price events)
  15. General reference statistics: WHO (dementia and depression prevalence), Alzheimer's Association (US prevalence)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.